I. CECOG Projects

• CECOG Clinical Protocols - ongoing
  

II. CECOG News

• Pemetrexed(ALIMTA ^TM), A novel Multi-targeted Antifolate
  
• Granulocyte Colony Stimulating Factors in Cancer Medicine: The Current Scenario
  
• Advancing the treatment of anaemia induced by cancer chemotherapy
  
• Trastuzumab: Targeted therapy to increase survival in metastatic breast cancer
  
• Taxotere^® (Docetaxel) as First-Line Treatment For Non-Small Cell Lung Cancer (NSCLC)

• New Breast Cancer Trial
  How to improve outcome of metastatic breast cancer patients?
  Docetaxel (Taxotere®) in locally advanced and/or metastatic breast cancer: an overview
  Role of gemcitabine (Gemzar®) in the treatment of breast cancer
• Ongoing Trials
  

• Summary of Recommendations
  Generated at the Consensus Meeting on Medical Treatment of Non-Small Cell Lung Cancer in Vienna
  
• ZD1839 (‘Iressa’): a new cancer treatment that targets the epidermal growth factor recepto

ASCO-2000 Review
What we did - and what we still should do in the future

A breakthrough
Adjuvant radiochemotherapy of gastric cancer

Gemcitabine + capecitabine in advanced pancreatic cancer

CECOG Activities

CECOG Studies

CECOG Interna

CECOG Meetings

Education
Report from CECOG/ESO Training Course

Gemcitabine-based therapy of invasive bladder cancer

SEMINARS IN CENTRAL EUROPE
ORGANIZED BY CECOG IN COOPERATION WITH THE
EUROPEAN SCHOOL OF ONCOLOGY - VIENNA OFFICE

In Cooperation with the European School of Oncology - Vienna Office and EORTC/BDTG

GET regimen followed by high-dose chemotherapy in breast cancer
(P.F.Conte)

Combination of Herceptin with Taxol: Breast Cancer Survival Data confirmed

Gemcitabine, carboplatin and paclitaxel: 100% response rate in ovarian cancer, with 58% complete remissions

FOLFOX regimen in resistant metastatic colon cancer

Triplets versus Doublets in NSCLC: An interim analysis

New agents for systemic treatment of early and metastatic breast cancer

Seminars in Central Europe

Cancer Treatment in the outpatient setting
(E.Ulsperger, Vienna)

Survival of BRCA1 Breast and Ovarian Cancer Patients: A Population-based Study from Southern Sweden
(Oskar T Johannson in: J.Clin.Oncol. 16(1998), 397-404)

ASCO 1998: New Data on Lung Cancer Treatment

Addition of Herceptin (Humanized antiHER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer; markedly increases anticancer activity: A randomized multinational controlled phase III trial.
D. Slamon, ASCO 1998